Faeth Therapeutics, Inc. (FTH) Ownership
FTH ownership summary
as of October 18, 2026- Institutions
- 80.9% of shares outstanding
- Insiders
- 4.95% of shares outstanding
- Shares outstanding
- 25.8M
- Float
- 18.5M shares available to trade
- Short interest
- 8.13% 2.1M shares short
- Days to cover
- 4.76 short interest up 56.8% vs prior month
- Institutions 80.94%
- Insiders 4.95%
- Other investors 14.12%
FTH top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Suvretta Capital Management, LLC | 7.82% | 2.0M | $38.0M | +2.0M (+5,747.1%) | June 30, 2026 |
| 2 | venBio Select Advisor LLC | 5.59% | 1.4M | $27.1M | +1.4M (0.0%) | June 30, 2026 |
| 3 | Baker Bros Advisors LP | 4.98% | 1.3M | $24.2M | +1.3M (0.0%) | June 30, 2026 |
| 4 | Balyasny Asset Management LLC | 4.03% | 1.0M | $19.6M | +1.0M (+6,331.3%) | June 30, 2026 |
| 5 | Cormorant Asset Management, LLC | 3.98% | 1.0M | $19.3M | +722,020 (+235.8%) | June 30, 2026 |
| 6 | Vivo Capital, LLC | 2.79% | 722K | $13.6M | — | June 30, 2026 |
| 7 | RA Capital Management, LLC | 2.79% | 722K | $13.6M | +722,020 (0.0%) | June 30, 2026 |
| 8 | Fairmount Funds Management LLC | 2.79% | 722K | $13.6M | +722,020 (0.0%) | June 30, 2026 |
| 9 | Logos Global Management LP | 2.79% | 722K | $13.6M | +692,020 (+2,306.7%) | June 30, 2026 |
| 10 | Caligan Partners LP | 2.44% | 629K | $11.8M | +503,465 (+399.6%) | June 30, 2026 |
| 11 | B Group, Inc | 2.36% | 610K | $11.5M | +610,169 (0.0%) | June 30, 2026 |
| 12 | Trails Edge Capital Partners, LP | 1.99% | 515K | $9.7M | +390,335 (+312.3%) | June 30, 2026 |
| 13 | Franklin Templeton Inc | 1.91% | 495K | $9.3M | +361,010 (+270.4%) | June 30, 2026 |
| 14 | ADAR1 Capital Management LLC | 1.40% | 361K | $6.8M | +361,010 (0.0%) | June 30, 2026 |
| 15 | Octagon Capital Advisors LP | 1.40% | 361K | $6.8M | +361,010 (0.0%) | June 30, 2026 |
| 16 | Marshall Wace Asset Management Ltd | 0.80% | 207K | $3.9M | +140,778 (+214.2%) | June 30, 2026 |
| 17 | Boxer Capital Management, LLC | 0.70% | 181K | $3.4M | +180,505 (0.0%) | June 30, 2026 |
| 18 | Patient Square Capital LP | 0.68% | 175K | $3.3M | +175,050 (0.0%) | June 30, 2026 |
| 19 | Affinity Asset Advisors, LLC | 0.56% | 144K | $2.7M | +144,404 (0.0%) | June 30, 2026 |
| 20 | Alyeska Investment Group, L.P. | 0.56% | 144K | $2.7M | +144,404 (0.0%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 19 holders added 12.0M shares and 0 cut 0.
FTH top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Polar Capital Biotech S Inc | 4.72% | 1.2M | $22.9M | +233,741 (+23.7%) | August 31, 2026 |
| 2 | Franklin Biotechnology Discv A(acc)USD | 1.30% | 337K | $6.3M | — | August 31, 2026 |
| 3 | State Street® SPDR® S&P® Biotech ETF | 0.84% | 216K | $4.1M | −4,100 (−1.9%) | September 30, 2026 |
| 4 | Franklin Biotechnology Discovery A | 0.70% | 181K | $3.4M | — | August 31, 2026 |
| 5 | Schwab US Small-Cap ETF™ | 0.40% | 102K | $1.9M | +63 (+0.1%) | September 30, 2026 |
| 6 | iShares Micro-Cap ETF | 0.30% | 77K | $1.4M | −532 (−0.7%) | September 30, 2026 |
| 7 | iShares Core S&P Total US Stock Mkt ETF | 0.11% | 29K | $551,310 | +30 (+0.1%) | September 30, 2026 |
| 8 | Schwab US Broad Market ETF™ | 0.05% | 12K | $233,327 | — | September 30, 2026 |
| 9 | Direxion Daily S&P Biotech Bull 3X ETF | 0.04% | 9,305 | $174,934 | +273 (+3.0%) | September 30, 2026 |
| 10 | Fidelity Nasdaq Composite ETF | 0.04% | 9,107 | $171,212 | — | September 30, 2026 |
| 11 | Fidelity Nasdaq Composite Index | 0.02% | 5,554 | $104,415 | −10,353 (−65.1%) | August 31, 2026 |
| 12 | Fidelity Extended Market Index | 0.02% | 4,536 | $85,277 | −24 (−0.5%) | August 31, 2026 |
| 13 | China Universal Gbl YLBJ QDII CNH | 0.01% | 3,600 | $67,680 | +3,600 (0.0%) | June 30, 2026 |
| 14 | Avantis US Small Cap Equity ETF | 0.01% | 2,976 | $55,949 | +142 (+5.0%) | September 30, 2026 |
| 15 | Fidelity Total Market Index | 0.01% | 1,416 | $26,621 | — | August 31, 2026 |
| 16 | Fidelity Series Total Market Index | <0.01% | 1,253 | $23,556 | — | August 31, 2026 |
| 17 | Texas Capital Texas Equity Index ETF | <0.01% | 556 | $10,453 | — | September 30, 2026 |
| 18 | JHVIT Total Stock Market Index I | <0.01% | 409 | $7,689 | +368 (+897.6%) | August 31, 2026 |
| 19 | LO Selection Balanced EUR MA | <0.01% | 265 | $4,982 | +35 (+15.2%) | August 31, 2026 |
| 20 | 1290 VT Micro Cap K | <0.01% | 210 | $3,948 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
FTH shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns FTH
Institutional investors own 80.9% of Faeth Therapeutics's shares and insiders 4.95%. The largest holder is Suvretta Capital Management, LLC with 7.82% of the shares (2.0M), as of June 30, 2026. Among the top 20 institutions, 19 added shares and 0 reduced their stake in the latest filings. Short interest is 8.13% of the float, or 4.76 days of average trading volume. The share count fell 14.0% since 2019.
Related: FTH analyst forecast, FTH key metrics. See the FTH stock overview for the latest quote and news.
FTH ownership FAQ
Who owns the most Faeth Therapeutics stock?
The largest shareholders of Faeth Therapeutics are Suvretta Capital Management, LLC (7.82%), venBio Select Advisor LLC (5.59%), Baker Bros Advisors LP (4.98%), Balyasny Asset Management LLC (4.03%), Cormorant Asset Management, LLC (3.98%).
What percentage of Faeth Therapeutics is owned by institutions?
Institutions hold 80.9% of Faeth Therapeutics's shares outstanding; insiders hold 4.95%.
Which funds own Faeth Therapeutics?
The largest fund holders of Faeth Therapeutics are Polar Capital Biotech S Inc (4.72%), Franklin Biotechnology Discv A(acc)USD (1.30%), State Street® SPDR® S&P® Biotech ETF (0.84%), Franklin Biotechnology Discovery A (0.70%), Schwab US Small-Cap ETF™ (0.40%).
What is Faeth Therapeutics's short interest?
2.1M shares of Faeth Therapeutics were sold short, 8.13% of the float; at the average daily volume it would take 4.76 days to cover.
How many shares of Faeth Therapeutics are outstanding?
Faeth Therapeutics has 25.8M shares outstanding, of which 18.5M are in the public float.